NEW YORK (GenomeWeb News) – Horizon Discovery said today that Millenium Pharmaceuticals will evaluate seven of Horizon’s X-MAN normal and mutant isogenic cell lines during an eight-month period.
 
The X-MAN cell lines may help speed the discovery of personalized cancer medicine, the company said. These cell lines are genetically defined in vitro models of human cancer and their matched normal cell types. They include a set of double cancer-gene "knock-in" lines designed to evaluate patient resistance to targeted agents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.